Company profile

EXCYTE (Beijing) Pharmaceutical Technology Development Co., Ltd.

Privately held: no public share price (Sino-US bispecific-antibody/CAR-T company (iexcyte.com), co-founded ~2021-2022, US subsidiary Excyte LLC. No public listing found; private. Sources: https://clinicaltrials.gov/study/NCT06574568 Entity resolved by asset-pipeline-v2.)

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
YKST02
Phase 2
BCMA x CD3Multispecific antibody
Multiple Myeloma

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.

Educational data tool. Figures are sourced from company filings and press releases: see each row's filing link. Share price is delayed (~15min) and refreshed periodically, not a real-time feed.